Reconsideration of Antinucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection Postvaccination for Mild COVID-19 Patients
Santosh Dhakal, Tong Yu, Anna Yin, Nora Pisanic, Zoe O Demko, Annukka A.R. Antar, Andrea L. Cox, Christopher D. Heaney, Yukari C. Manabe, Sabra L. Klein
Abstract
Antinucleocapsid (anti-N) immunoglobulin G antibody responses were lower in plasma and oral fluid after severe acute respiratory syndrome coronavirus 2 infection in vaccinated patients compared with patients infected before vaccination or infected without vaccination. This raises questions about the long-term use of anti-N antibodies as a marker for natural infection for surveillance.
Topics & Concepts
MedicineAntibodyCoronavirus disease 2019 (COVID-19)VaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyVirology2019-20 coronavirus outbreakImmunoglobulin GCoronavirusOutbreakPathologyInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing